New Step by Step Map For Imipenem
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate numerous intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key trial goals were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis